OR WAIT 15 SECS
The CDMO’s new blow-fill-seal machinery at its Kaysersberg site is now operational.
Contract development and manufacturing organization (CDMO), Recipharm, announced on Mar. 14, 2018 that its new blow-fill-seal machinery is now operational following a substantial investment in 2017 at its facility in Kaysersberg, France. The EUR18-million investment adds a new blow-fill-seal high-speed filling and packaging line to the site, taking the total number of lines to eight and increasing the facility’s manufacturing capacity by 200 million unit doses a year. In addition, the investment adds 2400 square meters to the facility, hence, creating space for three more machines, which will enable the site to manufacture more than 1.2 billion unit doses a year.
“This latest investment is in direct response to customer demand for single-dose and sterile manufacturing services, such as aseptic processing for eye care and ear care products, particularly from markets such as the US, Turkey, Australia, and Canada,” Yves Buelens, general manager at Recipharm’s Kaysersberg site, noted in a press statement. “This project was supported by the Region Grand Est and the CCI Alsace Eurométropole as part of employment-related actions.”
“Recipharm has only owned the facility for two years and during that time, [we] have taken some very fast and positive decisions to invest in Kaysersberg. We have worked hard to develop a flexible service that can cater for even the most complex of projects. Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand,” Buelens added.
Recipharm’s Kaysersberg facility, located in Alsace, France, specializes in blow-fill-seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications.